Dr. Samuels Replies
TO THE EDITOR: We agree with Drs. Grootheest and Cath that hoarding behavior may be heterogeneous, "possibly with subtypes related and subtypes unrelated to OCD." Indeed, on page 498 of our article, we noted that hoarding behavior can occur in conditions other than OCD, and we wrote that "we suspect that hoarding behavior itself is heterogeneous, and that the etiology of hoarding behavior is different in various syndromes." However, as noted by Dr. Saxena, all of the families in our cohort were recruited because they had two or more relatives affected with OCD, and thus OCD was overrepresented in the hoarding participants. On page 497, we suggested that Zhang et al. (1) may have found different linkage peaks for hoarding in their study because they selected families with multiple siblings affected with Tourette's syndrome, not OCD (1). Certainly, more work is needed in order to refine the phenotypic definition of hoarding, including the clinical features outlined by Dr. Saxena.
As pointed out by Drs. Van Grootheest and Cath, there was a range of severity in the hoarding individuals in our cohort, but the majority (68%) reported spending at least 1 hour per day and/or experiencing moderate, severe, or extreme distress that was frequent and disturbing during the worst period of their hoarding behavior.
We stand by our conclusion that the findings of our study suggest that a region on chromosome 14 is linked to compulsive hoarding behavior in these OCD families. We hypothesize that there is a genetic variant in this region that increases the risk of hoarding behavior in individuals who are susceptible to OCD. Additional genetic studies are required to replicate these findings and to characterize the genetic variant that may be involved. Aripiprazole-Induced Tardive Dyskinesia: The Role of Tamoxifen TO THE EDITOR: Aripiprazole is the newest atypical antipsychotic, which acts as a partial dopamine D 2 receptor agonist, partial 5-HT1A agonist, and 5-HT2A antagonist (1). There has been one case report of aripiprazole-induced tardive dyskinesia (2). We report a unique case of aripiprazole-induced tardive dyskinesia, with a possible role of concomitant tamoxifen use. There have been case reports on improvement of tardive dyskinesia with aripiprazole (2, 3). The partial agonist effect
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ajp.psychiatryonline.org on dopamine D 2 receptors and the lack of dopamine receptor upregulation at the nigrostriatal dopamine system were hypothesized as favorable effects of aripiprazole in patients with tardive dyskinesia (3).
Tamoxifen, a selective estrogen receptor modulator with mixed agonist/antagonist action, is used in the prevention and treatment of breast cancer (4) . Animal studies have shown a neuroprotective role of estrogen and tamoxifen at the nigrostriatal dopamine pathway; however, this finding has not been ubiquitous (5, 6) . Increased dopamine release (directly or indirectly through modulating dopamine receptor function) and modulation of membrane dopamine transporter activity have been postulated as some of the neuroprotective mechanisms of estrogen (5, 6).
We hypothesize that, in our patient-in addition to known risk factors (i.e., female gender, advanced age)-tamoxifen-induced dopaminergic action in the nigrostriatal dopamine system resulted in the loss of partial dopamine agonist effect of aripiprazole, which contributed to the development of tardive dyskinesia. Presently, the exact mechanisms remain unclear to us. In contradiction, estrogen has been previously reported to reduce tardive dyskinesia by suppressing dopamine receptor supersensitivity induced by typical antipsychotics (7).
In conclusion, it is important to note that aripiprazole can be associated with tardive dyskinesia. The relationship between estrogen, antipsychotics, and tardive dyskinesia remains to be examined.
